Gossamer Bio Inc (NASDAQ:GOSS)
| 1.17 Delayed Data As of Jun 09 |  -0.09 / -7.14%Today’s Change | 0.91 Today|||52-Week Range 15.20 | -46.08% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $124.1M |
Company Description
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 25, 2015 and is headquartered in San Diego, CA.
Contact Information
Gossamer Bio, Inc. 3013 Science Park Road San Diego California 92121 |
Employees
Shareholders
| Other institutional | 59.96% |
| Individual stakeholders | 17.77% |
| Mutual fund holders | 15.28% |
Top Executives
| Faheem Hasnain | Chairman, President & Chief Executive Officer |
| Bryan Giraudo | Chief Operating & Financial Officer |
| Christian Waage | EVP-Technical Operations & Administration |
| Richard Aranda | Chief Medical Officer |
| Laura Carter | Chief Scientific Officer |
